TY - JOUR
T1 - National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
AU - Krilov, Leonard R
AU - Fergie, Jaime
AU - Goldstein, Mitchell R.
AU - McLaurin, Kimmie K
AU - Wade, Sally
AU - Diakun, David
AU - Kong, Amanda
N1 - Background: The 2014 American Academy of Pediatrics (AAP) policy statement on respiratory syncytial virus immunoprophylaxis (RSV IP) recommended against its use in infants 29-34 weeks gestational age (wGA) without chronic lung disease or bronchopulmonary dysplasia (CLD/BPD) or congenital heart disease (CHD).
PY - 2017/10/1
Y1 - 2017/10/1
N2 - respiratory syncytial virus immunoprophylaxis (RSV IP) recommended against its use in infants 29–34 weeks gestational age (wGA) without chronic lung disease or bronchopulmonary dysplasia (CLD/BPD) or congenital heart disease (CHD). This study examined the impact of these changes by evaluating RSV IP use and bronchiolitis hospitalization rates among full-term (FT) and preterm (PT) infants 29–34 wGA in the 2014–15 RSV season relative to previous seasons. Methods. Infants born 7/1/2009 to 6/30/2015 were identified in the MarketScan Multistate Medicaid (MED) and Commercial (COM) databases; DRG and ICD-9-CM codes were used to select FT and PT infants without CLD/BPD or CHD. Outpatient RSV IP use was identified by drug and administration codes. Bronchiolitis hospitalizations were identified by diagnosis codes (466.11 and 466.19) during the RSV season (Nov–Mar) and summarized by chronologic age (CA). Hospitalization rates were calculated per 100 infant-seasons, and statistical significance was tested using generalized linear regression models with Poisson error, log link, and log offset for exposure time. Results. 1.1 mil MED and 1.0 mil COM births were identified; 5.2% MED and 4.8% COM infants were born at 29–34 wGA. RSV IP use decreased among MED and COM infants 29–34 wGA (P < .01) in 2014–15 compared with 2013–14. Bronchiolitis hospitalization rates increased for MED and COM infants 29–34 wGA in 2014–15 compared with 2013–14 (rate ratios .05). Absolute increases were greatest for infants 29–30 wGA and
AB - respiratory syncytial virus immunoprophylaxis (RSV IP) recommended against its use in infants 29–34 weeks gestational age (wGA) without chronic lung disease or bronchopulmonary dysplasia (CLD/BPD) or congenital heart disease (CHD). This study examined the impact of these changes by evaluating RSV IP use and bronchiolitis hospitalization rates among full-term (FT) and preterm (PT) infants 29–34 wGA in the 2014–15 RSV season relative to previous seasons. Methods. Infants born 7/1/2009 to 6/30/2015 were identified in the MarketScan Multistate Medicaid (MED) and Commercial (COM) databases; DRG and ICD-9-CM codes were used to select FT and PT infants without CLD/BPD or CHD. Outpatient RSV IP use was identified by drug and administration codes. Bronchiolitis hospitalizations were identified by diagnosis codes (466.11 and 466.19) during the RSV season (Nov–Mar) and summarized by chronologic age (CA). Hospitalization rates were calculated per 100 infant-seasons, and statistical significance was tested using generalized linear regression models with Poisson error, log link, and log offset for exposure time. Results. 1.1 mil MED and 1.0 mil COM births were identified; 5.2% MED and 4.8% COM infants were born at 29–34 wGA. RSV IP use decreased among MED and COM infants 29–34 wGA (P < .01) in 2014–15 compared with 2013–14. Bronchiolitis hospitalization rates increased for MED and COM infants 29–34 wGA in 2014–15 compared with 2013–14 (rate ratios .05). Absolute increases were greatest for infants 29–30 wGA and
UR - https://idsa.confex.com/idsa/2017/webprogram/Paper64815.html
UR - https://www.mendeley.com/catalogue/21a11332-8932-3bea-b5d3-ebf7802d3f01/
U2 - 10.1093/ofid/ofx163.1863
DO - 10.1093/ofid/ofx163.1863
M3 - Meeting abstract
VL - 4
SP - S695-S695
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - suppl_1
ER -